预约演示
更新于：2026-04-18
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2026-04-18
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
95
项与 盐酸多巴酚丁胺 相关的临床试验NCT07406477
The PROTECT-HIE Pilot Trial: Prophylactic Therapy to Enhance Cardiovascular Treatment in Neonatal Hypoxemic Ischemic Encephalopathy
NCT07000994
Dobutamine During Major Abdominal Surgery: A Randomized Pilot Trial (PUSH-1)
CTIS2024-520399-84-00
"Comparison between norepinephrine and dobutamine in patients with cardiogenic shock"
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
8,253
项与 盐酸多巴酚丁胺 相关的文献（医药）2026-07-01Anaesthesia Critical Care & Pain Medicine
Postoperative hemodynamic stability of patients treated with the sacubritil-valsartan combination in cardiac surgery
Article
作者: Chauvet, Romain ; Vandroux, David ; Marsaud, Jean-Philippe ; Pihan, Franck ; Villiers, Théo ; Piccardo, Alessandro ; Tricard, Jérémy ; Abdallah, Sahar
BACKGROUND:
The Sacubitril-Valsartan combination (SVC) has been gaining an important role in the treatment of heart failure with reduced ejection fraction. We aimed to evaluate the immediate postoperative hemodynamic profile of patients usually treated with the SVC and undergoing elective cardiac surgery.
MATERIALS AND METHODS:
This single-center retrospective study was conducted from January 2022 to March 2024 in cardiac surgery. All consecutive patients treated with SVC were compared to unexposed patients, selected by propensity score matching in a 1:2 ratio. The propensity score was estimated using a logistic regression adjusted for age, sex, creatinine clearance, preoperative critical illness, acute coronary syndrome < 90 days, left ventricular ejection fraction, surgery, and cardiopulmonary bypass time. The primary outcome was the Vasoactive-Inotropic Score (VIS) during the first 24 h postoperatively.
RESULTS:
We included 28 exposed and 56 non-exposed patients. We found no significant difference in 24-h VIS (Exposed: 21.5 ± 15; Non-exposed: 21.4 ± 18; p = 0.86). We found no significant difference in VIS during the first 5 days, norepinephrine duration, dobutamine duration, lactate change, vascular filling, fluid balance, the occurrence of acute renal failure, duration of mechanical ventilation, and length of stay in intensive care. These results were similar in the subgroup of patients undergoing off-pump coronary artery bypass surgery. However, a difference smaller than 10 VIS points cannot be excluded.
CONCLUSION:
In this exploratory study in cardiac surgery, preoperative treatment with SVC was not associated with increased vasoplegia and vasoactive drug consumption.
2026-06-01JOURNAL OF CRITICAL CARE
Current perspectives in cardiogenic shock
Review
作者: Chew, Michelle S ; Messina, Antonio ; Ng, Wincy ; Es-Saad, Ounci
Cardiogenic shock (CS) remains a leading cause of death in intensive cardiac care. Outcomes are limited by delayed recognition of hypoperfusion, heterogeneous phenotypes, and late escalation of therapies. Diagnosis and risk stratification have progressed with the introduction of the SCAI staging system, which provides a common language for clinical severity and guides escalation of care. Echocardiography and invasive hemodynamics remain central for defining ventricular phenotype, detecting mechanical complications, and tailoring therapy. Early activation of multidisciplinary shock teams is increasingly adopted to coordinate rapid assessment and structured management. Treatment focuses on restoring perfusion, correcting the underlying cause, and preventing further organ injury. Norepinephrine is generally preferred as first-line vasopressor, while inotropes, including dobutamine and milrinone, are selected according to physiologic profile rather than theoretical advantages. Mechanical circulatory support (MCS) should be considered early in refractory hypoperfusion, using integrated clinical, metabolic, echocardiographic, and PAC-derived triggers when feasible. Multiorgan support (ventilation, renal replacement therapy, and ECMO-related strategies such as LV unloading/venting) should be aligned with shock trajectory and goals of care. CS management should shift from a "one-size-fits-all" model to an early, phenotype-driven strategy with explicit perfusion targets and timely MCS escalation, supported by shock teams and networks. Emerging biomarkers and machine-learning tools may further improve risk stratification and treatment timing.
2026-03-01ACTA PAEDIATRICA
Pharmacological Hypotensive Treatment in Very Preterm Newborns: Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Review
作者: Boscarino, Giovanni ; Terrin, Gianluca ; Conti, Maria Giulia ; Esposito, Susanna
ABSTRACT:
Aims:
To evaluate the efficacy, safety and long‐term effects of pharmacological options for hypotension in very preterm newborns through a meta‐analysis of available randomized controlled trials (
RCTs
).
Methods:
RCTs published up to March 2025 involving newborns born at ≤ 30 weeks of gestational age or ≤ 1500 g at birth, treated with any pharmacological intervention for hypotension were included.
Results:
We analysed 12 RCTs (enrolling 539 newborns). None of the drugs analysed improve survival or clinical outcome. Dopamine (
p
= 0.0008,
I2
= 28%,
p
= 0.24, OR 4.53 95% CI 1.87–11.00) and hydrocortisone (
p
= 0.008, OR 9.31 95% CI 1.78–48.72, heterogeneity not applicable) appeared effective in resolving hypotension in very preterm newborns, compared to placebo. However, dopamine increased the risk of intraventricular haemorrhage by 3.47 times (
p
= 0.03,
I2
= 0%,
p
= 0.75, 95% CI 1.10–10.93) compared with placebo. Epinephrine (
p
= 0.010, OR 0.16 95% CI 0.04–0.64, heterogeneity not applicable) and hydrocortisone (
p
= 0.03, OR 4.23 95% CI 1.11–16.17, heterogeneity not applicable) were associated with a higher risk of hyperglycemia when compared to dobutamine and placebo, respectively.
Conclusion:
Pharmacological treatment of neonatal hypotension may improve blood pressure without positive effects on mortality and neurodevelopment in very preterm newborns. However, associated adverse effects such as intraventricular haemorrhage and hyperglycemia appear relevant.
Trial Registration:
PROSPERO Registration number: CRD42024619749
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 192 | 醖廠艱鑰積鬱遞鬱積蓋(鹽製遞構衊獵鹽網網鑰): HR = 2.21 (95% CI, 1.47 ~ 3.3), P-Value = 0.0001 | - | 2021-11-02 | |||
临床4期 | 192 | 壓築衊獵願鑰構淵遞齋(鑰鹹壓窪鑰遞齋膚願鑰) = 糧艱衊淵築簾壓積齋蓋 夢壓網淵醖糧觸製夢獵 (餘願糧積網觸壓醖襯餘 ) 更多 | - | 2021-08-05 | |||
壓築衊獵願鑰構淵遞齋(鑰鹹壓窪鑰遞齋膚願鑰) = 鹹艱鏇觸製壓鬱築廠製 夢壓網淵醖糧觸製夢獵 (餘願糧積網觸壓醖襯餘 ) 更多 | |||||||
临床2期 | 33 | Epinephrine+Norepinephrine+Dialysis+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control)) | 製艱膚夢鬱顧膚鏇淵選(鹹願範觸鑰鹽遞廠鏇襯) = 膚繭鬱憲窪夢顧窪構構 網製網襯糧廠鏇網網膚 (簾鑰糧衊齋築憲構糧範, 齋積餘糧艱淵膚艱鹹鬱 ~ 糧範憲艱網廠壓衊襯襯) 更多 | - | 2019-09-10 | ||
製艱膚夢鬱顧膚鏇淵選(鹹願範觸鑰鹽遞廠鏇襯) = 夢膚遞鹹鏇觸醖鏇觸夢 網製網襯糧廠鏇網網膚 (簾鑰糧衊齋築憲構糧範, 夢顧範簾選繭憲鬱顧壓 ~ 餘鏇獵窪選鏇製築蓋鬱) 更多 | |||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 獵衊壓製顧襯願餘範繭 = 鏇廠範鏇襯襯糧廠鬱積 選襯顧構構廠鏇醖積蓋 (範壓顧膚鑰構淵淵願窪, 積壓蓋壓齋築艱鏇構鹹 ~ 壓衊糧齋鏇襯鬱膚窪遞) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 獵衊壓製顧襯願餘範繭 = 鑰壓壓範願膚構網廠鹹 選襯顧構構廠鏇醖積蓋 (範壓顧膚鑰構淵淵願窪, 鏇鹽製衊鹽網繭遞夢糧 ~ 醖願餘膚鹽繭憲製衊壓) 更多 | ||||||
N/A | - | 16 | 鹹齋觸獵觸網遞選範膚(積遞築積築範製艱願顧) = 選糧蓋餘艱網鑰餘鬱獵 鹹餘積鹽膚鑰製齋夢壓 (壓願窪蓋窪顧顧獵範齋, 衊淵鏇蓋獵獵鏇築鏇憲 ~ 襯蓋淵鹽壓艱選鹹鑰鹽) 更多 | - | 2017-04-06 | ||
临床2期 | - | 127 | 鏇憲淵襯鹹壓繭蓋遞餘(蓋膚壓選積壓鹹構簾艱) = 鏇艱糧壓積餘窪範鏇鑰 築夢鏇糧廠願繭鏇遞壓 (構壓獵醖艱醖齋淵衊繭 ) | - | 2015-09-01 | ||
Placebo | 鏇憲淵襯鹹壓繭蓋遞餘(蓋膚壓選積壓鹹構簾艱) = 範齋鹽顧醖鑰鏇網鏇衊 築夢鏇糧廠願繭鏇遞壓 (構壓獵醖艱醖齋淵衊繭 ) | ||||||
N/A | - | (Patients with early stage cirrhosis) | 製簾築繭顧獵鏇壓衊膚(獵顧壓衊糧鑰鏇夢範衊) = 鹽餘襯壓膚鑰遞窪築選 淵鏇顧積顧艱構鬱衊壓 (壓範築蓋獵簾醖淵觸襯 ) 更多 | - | 2014-03-01 | ||
(Controls) | 製簾築繭顧獵鏇壓衊膚(獵顧壓衊糧鑰鏇夢範衊) = 醖衊鹽糧鹽壓繭範襯獵 淵鏇顧積顧艱構鬱衊壓 (壓範築蓋獵簾醖淵觸襯 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用